Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study.

Hematol Oncol · 2025 · PMC11789454 · PMID 39898517

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significanceno p-value reported

At univariable analysis, none of the factors indicated in Figure S1A showed any statistically significant association with PFS, although age > 70 years and receiving more than two prior lines of therapy approached borderline significance.

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.